Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real life experiences of a PK dosing study-Challenges and lessons learned.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Limiting Factors in the Advancement of Science as Observed in the History of Embryology.

The Yale journal of biology and medicine·2011
Same author

Science and technology in China's far south-east.

Nature·2010
Same author

SUBSTANCES PROMOTING NORMAL AND ABNORMAL GROWTH.

British medical journal·2010
Same author

International cooperation in the medical sciences and UNESCO.

Bulletin der Schweizerischen Akademie der Medizinischen Wissenschaften·2010
Same author

New Advances in the Chemistry and Biology of Organized Growth: (Section of Pathology).

Proceedings of the Royal Society of Medicine·2009

Related Experiment Video

Updated: Jul 16, 2026

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Integrating Patient-Centred Research in the Canadian Cancer Trials Group.

J Needham1, J Taylor1, D Nomikos1

  • 1Canadian Cancer Trials Group, Queen's University, Kingston, ON K7L 3N6, Canada.

Current Oncology (Toronto, Ont.)
|January 26, 2021
PubMed
Summary

Engaging patients as partners in cancer research enhances patient-centred care. The Canadian Cancer Trials Group (CCTG) improved patient engagement through a phased approach, leading to better trial accrual and funding.

Keywords:
cancerclinical trialspatient and public engagementpatient representativespatient-centred researchstakeholder engagement

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Three-Dimensional Culture Assay to Explore Cancer Cell Invasiveness and Satellite Tumor Formation
09:23

Three-Dimensional Culture Assay to Explore Cancer Cell Invasiveness and Satellite Tumor Formation

Published on: August 18, 2016

Related Experiment Videos

Last Updated: Jul 16, 2026

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Three-Dimensional Culture Assay to Explore Cancer Cell Invasiveness and Satellite Tumor Formation
09:23

Three-Dimensional Culture Assay to Explore Cancer Cell Invasiveness and Satellite Tumor Formation

Published on: August 18, 2016

Area of Science:

  • Health Services Research
  • Patient Engagement in Clinical Trials
  • Cancer Research Strategy

Background:

  • Patient-centered care necessitates meaningful patient involvement in healthcare research.
  • Previous patient engagement efforts in research often resulted in tokenism, missing potential benefits.
  • Understanding the value and optimal methods for patient partnership in research is crucial.

Purpose of the Study:

  • To describe the Canadian Cancer Trials Group's (CCTG) strategy for implementing patient centricity and engagement.
  • To outline the benefits realized from enhanced patient partnership in cancer research.
  • To detail the evolution of patient roles from passive attendees to active collaborators.

Main Methods:

  • A gap analysis identified needs for role clarity, strategic alignment, training, and support for Patient Representatives.
  • A three-phase implementation plan was developed, progressively increasing the level of patient engagement.
  • Engagement levels were advanced using the International Association for Public Participation (IAP2) scale from 'Inform' to 'Collaborate'.

Main Results:

  • Significant contributions were made to increasing patient accrual in CCTG clinical trials.
  • Enhanced patient engagement led to increased CCTG grant funding.
  • The implemented practices gained recognition and were adopted within Canada and internationally.

Conclusions:

  • A structured, phased approach effectively enhances patient engagement in cancer research governance.
  • Meaningful patient partnership demonstrably improves research outcomes, including trial recruitment and funding.
  • The CCTG model provides a scalable framework for advancing patient centricity in clinical trials globally.